|
|
|
| home > ebr > autumn 2001 > innovative facility concepts for biopharmaceutical multipurpose pilot and production plants |
|
|
 PUBLICATIONS |
European Biopharmaceutical Review
|
| The manufacturing requirements of biologics, raw materials, starting materials, excipients and APIs (secondary metabolite, prokaryat, cell culture, transgenic plants and animals, blood products, vaccines and so on), and the dosage form required (aseptic filling, vials, ampoules, syringes, pulmonary systems, transdermal systems etcetera), strongly influence the design concept for pharmaceutical facilities. The greatest influential factors on the design of such facilities are the purpose of the plant (mono or multipurpose), and the size of the plant (the production of cytokines requires less equipment and equipment that is smaller than bulk or rHSA, for example). The production of clinical trial material also needs a smaller plant than for market supply. |
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
By Dr Hermann Allgaier, Managing Director of Operations at LSMW GmbH
Dr Hermann Allgaier is the Managing Director of Operations for LSMW GmbH, a company providing consultancy, design, construction and validation services for the pharmaceutical and biotech industry. His 17 years of experience include upstream and downstream processing, engineering, analytical services and internal compliance. He was Responsible Head and led the worldwide process development of new chemical entities at Boehringer Ingelheim in Germany.
Dr Allgaier has made numerous presentations and has had work published in the
areas of biopharmaceutical development, manufacturing and general compliance. He is a Member of PDA, ISPE and APV, where he heads the biopharmaceutical section. Dr Allgaier studied Biochemistry at the University of Tübingen, where he received the Friedrich Weygand Award for his PhD work in the field of peptide antibiotics.
|
|
|
|
|
|
 |
Industry Events |
 |
EMBALLAGE 2012
19-22 November 2012, Paris Nord Villepinte, France
EMBALLAGE has clearly delineated sectors to make the decision-maker’s task easier when visiting and to highlight all the industry’s know-how: machinery and packaging for the food and cosmetics sectors, health solutions and luxury packaging and containers, etc. Hence, EMBALLAGE provides a bespoke solution for each industry
More info >> |
|
 |
News and Press Releases |
 |
AMRI Announces Preferred Provider Agreement with BioPontis Alliance LLC
AMRI, a global contract services organization, announced today that it has entered into a preferred provider agreement with BioPontis Alliance LLC. The agreement is aimed at supporting BioPontis’ mission to bridge the gap between early-stage research and technologies being discovered and developed in academia and other research entities. AMRI will provide its services in small molecule discovery, development, and manufacturing in BioPontis’ drug discovery research programs. The agreement also supports the need for proof-of-concept data that is required in the current pharmaceutical company licensing environment. The goal of BioPontis Alliance is to identify promising early stage product opportunities and utilize a preferred network of CROs and leading research companies to apply appropriate expertise to develop these opportunities enough to attract pharmaceutical company licensing partners.
More info >> |
|
|
